Do A - Search Results

1

Broadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine.

Do A, Xu J. Do A, et al. Dig Dis Sci. 2023 Mar;68(3):725-728. doi: 10.1007/s10620-023-07827-2. Epub 2023 Jan 21. Dig Dis Sci. 2023. PMID: 36670325 No abstract available.

2

Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system.

Ilagan-Ying YC, Xu J, Lim JK, Do A. Ilagan-Ying YC, et al. Among authors: do a. Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):424-429. doi: 10.1097/MEG.0000000000001758. Eur J Gastroenterol Hepatol. 2021. PMID: 32433419 Free PMC article.

3

Increased Mortality in Patients Undergoing Inpatient Endoscopy During the Early COVID-19 Pandemic.

Ilagan-Ying YC, Almeida MN, Kahler-Quesada A, Ying L, Hughes ML, Do A, Hung KW. Ilagan-Ying YC, et al. Among authors: do a. Dig Dis Sci. 2022 Nov;67(11):5053-5062. doi: 10.1007/s10620-022-07414-x. Epub 2022 Feb 19. Dig Dis Sci. 2022. PMID: 35182250 Free PMC article.

4

Clinical Phenotyping and the Application of Precision Medicine in MAFLD.

Saffo S, Do A. Saffo S, et al. Among authors: do a. Clin Liver Dis (Hoboken). 2022 May 23;19(6):227-233. doi: 10.1002/cld.1199. eCollection 2022 Jun. Clin Liver Dis (Hoboken). 2022. PMID: 35795621 Free PMC article. Review.

5

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review.

Chen G, Banini B, Do A, Lim JK. Chen G, et al. Among authors: do a. Clin Mol Hepatol. 2023 Feb;29(Suppl):S319-S332. doi: 10.3350/cmh.2022.0366. Epub 2022 Dec 14. Clin Mol Hepatol. 2023. PMID: 36517000 Free PMC article.

6

Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI.

Do A, Lim JK. Do A, et al. Hepatology. 2023 Jul 1;78(1):6-7. doi: 10.1097/HEP.0000000000000360. Epub 2023 Mar 13. Hepatology. 2023. PMID: 36896961 No abstract available.

7

Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Chen G, Banini BA, Do A, Gunderson C, Zaman S, Lim JK. Chen G, et al. Among authors: do a. Genes (Basel). 2023 Sep 17;14(9):1811. doi: 10.3390/genes14091811. Genes (Basel). 2023. PMID: 37761951 Free PMC article. Review.

8

Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.

Ilagan-Ying YC, Banini BA, Do A, Lam R, Lim JK. Ilagan-Ying YC, et al. Among authors: do a. Curr Gastroenterol Rep. 2023 Oct;25(10):213-224. doi: 10.1007/s11894-023-00883-8. Epub 2023 Sep 28. Curr Gastroenterol Rep. 2023. PMID: 37768417 Review.

9

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).

Do A, Zahrawi F, Mehal WZ. Do A, et al. Nat Rev Drug Discov. 2024 Nov 28. doi: 10.1038/s41573-024-01084-2. Online ahead of print. Nat Rev Drug Discov. 2024. PMID: 39609545 Review.

10

Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.

Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Do A, et al. Expert Opin Drug Discov. 2021 Feb;16(2):125-134. doi: 10.1080/17460441.2020.1811674. Epub 2020 Oct 22. Expert Opin Drug Discov. 2021. PMID: 33086894 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

527 results

Search Page

Filters